A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial hypertension
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms FUTURE 6
- Sponsors Actelion Pharmaceuticals
- 08 Sep 2017 New trial record
- 09 Dec 2016 As per the correspondence between Actelion Clinical Trial Disclosure Team and EudraCT registration desk dated 9 Dec 2016, this trial was never initiated and no patients were included in this trial.